Actinium Pharmaceuticals (NASDAQ:ATNM) Stock Price Down 3.6%

Actinium Pharmaceuticals, Inc. (NASDAQ:ATNM) traded down 3.6% during mid-day trading on Friday . The stock traded as low as $0.26 and last traded at $0.27, 129,894 shares changed hands during mid-day trading. A decline of 97% from the average session volume of 4,954,282 shares. The stock had previously closed at $0.28.

The firm’s 50-day moving average price is $0.24.

Actinium Pharmaceuticals (NASDAQ:ATNM) last announced its earnings results on Tuesday, November 12th. The company reported ($0.04) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.04).

Actinium Pharmaceuticals Company Profile (NASDAQ:ATNM)

Actinium Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, Iomab-B that is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant.

Further Reading: Certificate of Deposit (CD) For Risk Adverse Investors?

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with's FREE daily email newsletter.